

5 February 2019

Deltex Medical Group plc
("Deltex Medical" or the "Company")

Director Dealing

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), was informed today that Nigel Keen, Chairman of the Company, had purchased 8,695,652 ordinary shares of 1 penny each in the Company ("Ordinary Shares") on 5 February 2019 at a price of 1.125 pence per Ordinary Share.

Following these transactions, Mr Keen's beneficial ownership is 62,918,762 Ordinary Shares, representing approximately 13 per cent. of Deltex Medical's issued ordinary share capital.

For further information, please contact:-

Deltex Medical Group plc

Nigel Keen, Chairman
Andy Mears, Chief Executive
Jonathan Shaw, Group Finance Director

01243 774 837

investorinfo@deltexmedical.com

Nominated Adviser & Broker

Arden Partners plc

Ciaran Walsh
Dan Gee-Summons

020 7614 5900

Joint Broker

Turner Pope Investments (TPI) Ltd

Andy Thacker

0203 621 4120

info@turnerpope.com

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal doppler monitoring ("ODM") (TrueVue Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in flow and measures such changes in 'real time'. Deltex Medical has been the only Group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue Doppler, which has been demonstrated to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Group goal

Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for high risk surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA - and through distribution arrangements in approximately 40 other countries.

[Note: This announcement contains inside information for the purposes of Article 7 of Regulation \(EU\) No 596/2014.](#)

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Names	Nigel Keen - Chairman
2	Reason for the notification	
a)	Position/status	See 1(a) above for position - classified as a PDMR of Deltex Medical
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Deltex Medial Group plc
b)	LEI	213800XN34P6LI8J6M39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary shares of 1 penny each ("Ordinary Shares")
b)	Identification code	GB0059337583
c)	Nature of the	

	transaction	Purchase of Ordinary Shares	
d)	Price(s) and volume(s)	Prices(s)	Volume(s)
		1.125 pence	8,695,652
d)	Aggregated information		
	- Aggregated volume	8,695,652	
	- Price	1.125 pence	
e)	Date of the transaction	5 February 2019	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	